Prof. Cuneyt Turkmen
6
reviews
The doctor carefully reviewed the results and gave recommendations. You can feel the great experience and confidence of the specialist. Thank you for your care.
02/02/2025
Professor Turkmen is a true expert in nuclear medicine. I recommend.
05/11/2024
Thanks to the accurate diagnosis, treatment was started quickly. The staff were also polite and well organized.
12/03/2024
The only downside was that I had to wait a bit for my turn. But the quality of the diagnostics is at a high level.
18/09/2023
Everything went without stress, the equipment is modern. You can sense the high standard of the clinic and the professionalism of the doctor.
27/06/2023
For us he is extremely valuable — a meticulous professional and an outstanding doctor. He cured my father and pushed back his disease for years.
We are very grateful to him.
Professor Cuneyt Turkmen — a Turkish nuclear medicine specialist focused on nuclear oncology and radionuclide therapy.
He has worked at the Department of Nuclear Medicine of Istanbul University Faculty of Medicine since 2002; in 2007 he received the European Board of Nuclear Medicine certification and the academic title of Associate Professor, and in 2014 the title of Full Professor. Alongside his academic work, he maintains clinical practice at major private hospitals — at Istanbul Florence Nightingale Hospital from 2015 to 2021, and at Memorial Şişli Hospital since 2021.
His clinical expertise covers modern radionuclide treatment methods: lutetium-177 PSMA for metastatic prostate cancer, yttrium-90 (radioembolization) for liver tumors, lutetium-177 DOTATATE for neuroendocrine tumors, phosphorus-32 OncoSil for pancreatic cancer, and alpha therapy with actinium-225.
He has authored 95 scientific articles (61 in international journals), 110 conference presentations, and 12 chapters in medical books. He regularly delivers presentations at congresses of the Turkish Society of Nuclear Medicine.
For a patient with metastatic prostate cancer, liver tumors, neuroendocrine tumors, or pancreatic cancer, this means access to one of Turkey’s most experienced specialists in modern radionuclide methods at a clinic with a licensed infrastructure.
Achievements and Awards
About Doctor Cuneyt Turkmen
Nuclear medicine (not surgical oncology).
Subspecialty areas: nuclear oncology and radionuclide therapy, theranostics, PET/CT diagnostics.
In particular: lutetium-177 PSMA for metastatic castration-resistant prostate cancer; yttrium-90 (radioembolization) for liver tumors; lutetium-177 DOTATATE for neuroendocrine tumors; phosphorus-32 OncoSil for pancreatic cancer; alpha therapy with actinium-225.
- 1992 — MD, Dokuz Eylül University Faculty of Medicine (Izmir).
- 1998–2002 — residency in nuclear medicine, Istanbul University Cerrahpaşa Faculty of Medicine.
- 2007 — academic title of Associate Professor.
- 2007 — Fellowship of the European Board of Nuclear Medicine.
- 2014 — academic title of Full Professor.
- Additional international fellowship — Sahlgrenska University Queen Silvia Hospital (Sweden).
- Since 2002 — Istanbul University Faculty of Medicine (Çapa), Department of Nuclear Medicine, academic position.
- 2015–2021 — Istanbul Florence Nightingale Hospital, Department of Nuclear Medicine.
- Since 2021 — Memorial Şişli Hospital, Department of Nuclear Medicine.
Main clinical areas: radionuclide therapy of metastatic prostate cancer (lutetium-177 PSMA, actinium-225); yttrium-90 radioembolization for hepatocellular carcinoma and liver metastases; lutetium-177 DOTATATE for neuroendocrine tumors; diagnostic PET/CT; yttrium-90 radiosynovectomy for hemophilic synovitis; phosphorus-32 OncoSil for unresectable pancreatic cancer.
- 95 scientific articles; 61 of them in international peer-reviewed journals.
- 110 conference presentations, 49 of which are international.
- 12 chapters in medical books.
Main directions of his research:
- yttrium-90 radioembolization of liver metastases;
- lutetium-177 DOTATATE dosimetry for neuroendocrine tumors;
- targeted FAP radionuclide therapy (lutetium-177 FAP104); yttrium-90 radiosynovectomy for hemophilic synovitis.
- Turkish Society of Nuclear Medicine (Türkiye Nükleer Tıp Derneği) — board member 2008–2014, active speaker at national congresses 2021–2025.
- European Board of Nuclear Medicine — Fellowship (2007).
Turkish Hemophilia Association (Türkiye Hemofili Derneği) — member of the scientific committee since 2005 to date. - Istanbul University Faculty of Medicine — participation in university committees: Quality Council (2012–2022), Employee and Patient Safety Committee (2012–2018), Bulletin Editorial Board (2012–2014).
- Member of the Nuclear Medicine Commission at the Turkish Medical Specialty Board (Tıpta Uzmanlık Kurulu) 2010–2014.
Memorial Şişli Hospital is the flagship hospital of the Memorial Healthcare Group network.
The hospital has a dedicated oncology and radiotherapy center, a robotic surgery center (the da Vinci system), and a fully equipped department of nuclear medicine where modern radionuclide therapies are performed — lutetium-177 PSMA for metastatic prostate cancer, yttrium-90 radioembolization for liver tumors, lutetium-177 DOTATATE for neuroendocrine tumors — as well as diagnostic PET/CT imaging.
The hospital admits patients from many countries and has long-standing experience in serving international patients.
For a patient with metastatic prostate cancer, liver tumors, neuroendocrine tumors, or pancreatic cancer where radionuclide therapy is indicated, this is an opportunity to receive treatment within one of the most technologically equipped radionuclide programs in Turkey at an internationally accredited hospital.
